">
Monday, 4 May 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 04 May 2026
News

Aussie discovery goes commercial

Posted 4 May 2026 PM

Specialised Therapeutics (ST) has secured the TGA’s approval for chronic graft-versus-host disease (cGCVHD) treatment Niktimvo, developed off the back of QIMR Berghofer scientists’ research, with the company currently “exploring” listing the drug on the PBS.

Assessed under the TGA’s priority review pathway, the first-in-class colony stimulating factor-1 receptor (CSF-1R) blocking antibody has been approved for the treatment of cGVHD after failure of at least two prior lines of systemic therapy in adult and paediatric patients six years and older weighing at least 40 kg.

To see the whole article, please login

Popular

Aussie pharma on the nose
High-flyers on the move in pharma
Which CAR T saved Sam Neill?
Blast from the past heads to PBAC
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home